{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Florez HJ"],"funding":["BLRD VA","NCATS NIH HHS","NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","National Institutes of Health","AstraZeneca","NIGMS NIH HHS","CSRD VA"],"pagination":["109188"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8917078"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["184"],"pubmed_abstract":["<h4>Aims</h4>We evaluated differences in participants with type 2 diabetes (T2DM) enrolled in the GRADE study at VA vs non-VA sites, focusing on cardiovascular risk factors and rates of diabetes care target achievements.<h4>Methods</h4>We compared baseline characteristics between participants at VA (n = 1216) and non-VA (n = 3831) sites, stratifying analyses by cardiovascular disease (CVD) history.<h4>Results</h4>VA and non-VA participants had similar diabetes duration (4.0 years), HbA1c (7.5%), and BMI (34 kg/m<sup>2</sup>); however, VA participants had more individuals ≥ 65 years (37.3% vs 19.8%, p < 0.001), men (90.0% vs 55.2%, p < 0.001), hypertension (75.8% vs 63.6%, p < 0.001), hyperlipidemia (76.6% vs 64.6%, p < 0.001), current smokers (19.0% vs 12.1%, p < 0.001), nephropathy (20.4% vs 17.0%, p < 0.05), albuminuria (18.4% vs 15.1%, p < 0.05), and CVD (10.4% vs 5.2%, p < 0.001). In those without CVD, more VA participants were treated with lipid (70.8% vs 59.5%, p < 0.001) and blood pressure (74.9% vs 65.4%, p < 0.001) lowering medications, and had LDL-C < 70 mg/dl (32.9% vs 24.2%, p < 0.05). Among those with CVD, more VA participants had BP < 140/90 (80.2% vs 70.1%, p < 0.05) after adjusting for demographics.<h4>Conclusion</h4>GRADE participants at VA sites had more T2DM complications, greater CVD risk and were more likely to be treated with medications to reduce it, leading to more LDL-C at goal than non-VA participants, highlighting differences in diabetes populations and care."],"journal":["Diabetes research and clinical practice"],"pubmed_title":["Differences in complications, cardiovascular risk factor, and diabetes management among participants enrolled at veterans affairs (VA) and non-VA medical centers in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE)."],"pmcid":["PMC8917078"],"funding_grant_id":["UL1 TR002378","UL1 TR002537","I01 CX001737","UL1 TR001425","UL1 TR002535","UL1 TR000439","UL1 TR001449","UL1 TR001108","I01 BX005831","UL1 TR001409","P30 DK020572","UL1 TR002243","P30 DK092926","UL1 TR002489","UL1 TR002345","P30 DK020541-44","UL1 TR002548","P30 DK017047","U54 GM104940","UL1 TR000445","UL1 TR002529","U34 DK088043","P30 DK072476","U01 DK098246","P30 DK079626","P30 DK020541"],"pubmed_authors":["Ghosh A","Park J","Wexler DJ","GRADE Research Group","Pop-Busui R","Aroda VR","Underkofler C","Hox SH","Krause-Steinrauf H","Killean T","Florez HJ","Rhee MK","McKee MD"],"additional_accession":[]},"is_claimable":false,"name":"Differences in complications, cardiovascular risk factor, and diabetes management among participants enrolled at veterans affairs (VA) and non-VA medical centers in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE).","description":"<h4>Aims</h4>We evaluated differences in participants with type 2 diabetes (T2DM) enrolled in the GRADE study at VA vs non-VA sites, focusing on cardiovascular risk factors and rates of diabetes care target achievements.<h4>Methods</h4>We compared baseline characteristics between participants at VA (n = 1216) and non-VA (n = 3831) sites, stratifying analyses by cardiovascular disease (CVD) history.<h4>Results</h4>VA and non-VA participants had similar diabetes duration (4.0 years), HbA1c (7.5%), and BMI (34 kg/m<sup>2</sup>); however, VA participants had more individuals ≥ 65 years (37.3% vs 19.8%, p < 0.001), men (90.0% vs 55.2%, p < 0.001), hypertension (75.8% vs 63.6%, p < 0.001), hyperlipidemia (76.6% vs 64.6%, p < 0.001), current smokers (19.0% vs 12.1%, p < 0.001), nephropathy (20.4% vs 17.0%, p < 0.05), albuminuria (18.4% vs 15.1%, p < 0.05), and CVD (10.4% vs 5.2%, p < 0.001). In those without CVD, more VA participants were treated with lipid (70.8% vs 59.5%, p < 0.001) and blood pressure (74.9% vs 65.4%, p < 0.001) lowering medications, and had LDL-C < 70 mg/dl (32.9% vs 24.2%, p < 0.05). Among those with CVD, more VA participants had BP < 140/90 (80.2% vs 70.1%, p < 0.05) after adjusting for demographics.<h4>Conclusion</h4>GRADE participants at VA sites had more T2DM complications, greater CVD risk and were more likely to be treated with medications to reduce it, leading to more LDL-C at goal than non-VA participants, highlighting differences in diabetes populations and care.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-05-09T22:38:10.25Z","creation":"2025-02-19T03:25:48.093Z"},"accession":"S-EPMC8917078","cross_references":{"pubmed":["34971663"],"doi":["10.1016/j.diabres.2021.109188"]}}